Answering the Call
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Meeting Slides
Guidelines
EOSINOPHILIC ESOPHAGITIS
Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference.
Dellon ES, et al. Gastroenterology. 2018;155(4):1022-1033.e10.
AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis.
Hirano I, et al. Gastroenterology. 2020;158(6):1776-1786.
Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters.
Rank MA, et al. Ann Allergy Asthma Immunol. 2020;124(5):424-440.e17.
HEREDITARY ANGIOEDEMA
US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema.
Busse PJ, et al. J Allergy Clin Immunol Pract. 2021;9(1):132-150.
Patient & Clinician Resources
EOSINOPHILIC ESOPHAGITIS
EoE Adaptive Behaviors Poster
American Partnership for Eosinophilic Disorders (Apfed)
Campaign Urging Research for Eosinophilic Disease (CURED)
National Organization for Rare Disorders
HEREDITARY ANGIOEDEMA
US Hereditary Angioedema Association
National Organization for Rare Disorders
Suggested Readings
EOSINOPHILIC ESOPHAGITIS
One-hour esophageal string test: a nonendoscopic minimally invasive test that accurately detects disease activity in eosinophilic esophagitis.
Ackerman SJ, et al. Am J Gastroenterol. 2019;114(10):1614-1625.
Phenotypic characterization of eosinophilic esophagitis in a large multicenter patient population from the Consortium for Food Allergy Research.
Chehade M, et al. J Allergy Clin Immunol Pract. 2018;6(5):1534-1544.e5.
Mechanisms of disease of eosinophilic esophagitis.
Davis BP, Rothenberg ME. Annu Rev Pathol. 2016;11:365-393.
A phase 3, randomized, 3-part study to investigate the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic esophagitis: results from part A.
Dellon ES. American College Gastroenterology Conference; October 26, 2020. Abstract LB3.
Diagnosis and treatment of eosinophilic esophagitis.
Gonsalves NP, Aceves SS. J Allergy Clin Immunol. 2020;145(1):1-7.
Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial.
Hirano I, et al. Clin Gastroenterol Hepatol. 2022;20(3);525-534.
Functional lumen imaging probe for the management of esophageal disorders: expert review from the clinical practice updates committee of the AGA Institute.
Hirano I, et al. Clin Gastroenterol Hepatol. 2017;15(3):P325-P334.
Type 2 inflammation in eosinophilic esophagitis: from pathophysiology to therapeutic targets.
Racca F, et al. Front Physiol. 2021;12:815842.
HEREDITARY ANGIOEDEMA
Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States.
Banerji A, et al. Ann Allergy Asthma Immunol. 2020;124(6):600-607.
Hereditary angioedema: new finding concerning symptoms, affected organs, and course.
Bork K, et al. Am J Med. 2006;119(3):267-274.
Hereditary angioedema.
Busse PJ, Christiansen SC. N Engl J Med. 2020;382(12):1136-1148.
Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study.
Farkas H, et al. Clin Transl Allergy. 2021;11(4):e12035.
Threshold-stimulated kallikrein activity distinguishes bradykinin- from histamine-mediated angioedema.
Lara-Marquez ML, et al. Clin Exp Allergy. 2018;48(11):1429-1438
sgp120 and the contact system in hereditary angioedema: a diagnostic tool in HAE with normal C1 inhibitor.
Larrauri B, et al. Mol Immunol. 2020;119:27-34.
The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression.
Lumry WR, et al. Allergy Asthma Proc. 2010;31(5):407-414.
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.
Riedl MA, et al. Allergy. 2020;75(11):2879-2887.
Ecallantide.
Zuraw B, et al. Nat. Rev Drug Discov. 2010;9(3):189-190.
Hereditary angioedema with normal C1 inhibitor: four types and counting.
Zuraw BL. J Allergy Clin Immunol. 2018;141(3):884-885.
Interactive PresentationCall a Colleague with Robert M. Genta, MD
Call a Colleague with Evan Dellon, MD, MPH
A Patient’s Journey In Her Own Words
Troyce Venturella, RN, CCM, MPH
Call a Colleague with Bruce L. Zuraw, MD
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Relevant Resources
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
A New Era in Precision Medicine
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Evolving Best Practices to Optimize Outcomes
Consensus and Controversies on the Road to Precision Medicine
New Strategies to Target Remission and Individualize Comprehensive Care
Targeting Immune Dysregulation and Delivering Comprehensive Care
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
The PCP’s Role in Timely Recognition and Referral
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Got it? Treat it!
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Debates and Discussions About Personalizing Patient Management
Using Imaging to Improve Patient Outcomes
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
The Emerging Role of the Diabetologist
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
From Guideline Recommendations to Daily Clinical Decision-Making
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Improving Patient Outcomes Through Shared Clinical Decision Making
Debates and Discussions About Pustular Disease Subtypes
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Debates & Discussions on the Evolving Role of JAK Inhibitors
Collaborative Care for Better Patient Outcomes
Why It Matters in OB/GYN Practice Today
Improving Patient Outcomes Through Shared Clinical Decision Making
Digging Deep on Shared Decision-Making
How the Pharmacist Can Make a Difference
Mechanistic Insights and Evolving Treatment Options
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Clinical Resource Center
The Evolving Role of JAK Inhibitors
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Unpacking the Evidence for Their Use Today and Tomorrow
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
Mechanistic Insights and Emerging Treatment Options
A PrEP Primer
A Foundation for Managed Care
A Focus on Exacerbation Prevention
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
Unlocking Novel Paths to Patient Care
Evolving Best Practices for Patient Management
Pathophysiology, Multimodal Management, and Shared Clinical Decision Making
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
The Increasing Role of JAK Inhibitors
An Interactive Learning Experience
Unlocking Novel Paths to Patient Care
Shared Decision-making in the Era of Biologics
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
From Comprehensive Patient Evaluations to Individualized Evidence-based Care
Preventing COPD Exacerbations to Improve Outcomes
A Multidisciplinary Online Mini-Curriculum
A Whole Patient Case Series
Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Evolving Best Practices for Pediatric Patients
A Case-Based Update
Interdisciplinary Strategies for Adult and Pediatric Patients
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
New Pathways to Optimize Patient Outcomes
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
From Patient Evaluations to New Targeted Therapies
Debates and Discussions About New Upstream Treatment Avenues
A Case-Based Update on Pediatric Patients
An Interactive Educational Journey
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
